Detalhe da pesquisa
1.
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Blood
; 143(24): 2490-2503, 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493481
2.
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Blood
; 141(17): 2127-2140, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758212
3.
JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
Blood
; 137(16): 2139-2151, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667305
4.
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.
Blood Adv
; 8(9): 2312-2325, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38295283
5.
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Hemasphere
; 7(5): e885, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37153874
6.
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 165(1): 26-33, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33542546
7.
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.
Cancers (Basel)
; 13(9)2021 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33946220
8.
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Cancers (Basel)
; 12(4)2020 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32272770